Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Validation of a one-page patient-reported Charlson comorbidity index questionnaire for upper aerodigestive tract cancer patients.

Habbous S, Chu KP, Harland LT, La Delfa A, Fadhel E, Sun B, Xu W, Wong A, Howell D, Ringash J, Waldron J, O'Sullivan B, Goldstein D, Huang SH, Liu G.

Oral Oncol. 2013 May;49(5):407-12. doi: 10.1016/j.oraloncology.2012.11.010. Epub 2013 Jan 4.

PMID:
23291295
2.

Evaluation of comorbidity in 9388 head and neck cancer patients: a national cohort study from the DAHANCA database.

Bøje CR, Dalton SO, Primdahl H, Kristensen CA, Andersen E, Johansen J, Andersen LJ, Overgaard J.

Radiother Oncol. 2014 Jan;110(1):91-7. doi: 10.1016/j.radonc.2013.11.009. Epub 2014 Jan 8.

PMID:
24412015
3.

Prognostic impact of pretherapeutic laboratory values in head and neck cancer patients.

Peter F, Wittekindt C, Finkensieper M, Kiehntopf M, Guntinas-Lichius O.

J Cancer Res Clin Oncol. 2013 Jan;139(1):171-8. doi: 10.1007/s00432-012-1320-1. Epub 2012 Sep 25.

PMID:
23007690
4.

Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status.

Habbous S, Harland LT, La Delfa A, Fadhel E, Xu W, Liu FF, Goldstein D, Waldron J, Huang SH, O'Sullivan B, Liu G.

Head Neck. 2014 Jun;36(6):802-10. doi: 10.1002/hed.23360. Epub 2013 Jul 30.

PMID:
23616414
5.

Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma.

Singh B, Bhaya M, Zimbler M, Stern J, Roland JT, Rosenfeld RM, Har-El G, Lucente FE.

Head Neck. 1998 Jan;20(1):1-7.

PMID:
9464945
6.

Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.

Goyal J, Pond GR, Galsky MD, Hendricks R, Small A, Tsao CK, Sonpavde G.

Urol Oncol. 2014 Jan;32(1):36.e27-34. doi: 10.1016/j.urolonc.2013.02.015. Epub 2013 May 16.

PMID:
23685020
7.

[Prognostic impact of Charlson comorbidity index obtained from medical records and claims data on 1-year mortality and length of stay in gastric cancer patients].

Kyung MH, Yoon SJ, Ahn HS, Hwang SM, Seo HJ, Kim KH, Park HK.

J Prev Med Public Health. 2009 Mar;42(2):117-22. doi: 10.3961/jpmph.2009.42.2.117. Korean.

8.

Modified Charlson comorbidity index for predicting survival after liver transplantation.

Volk ML, Hernandez JC, Lok AS, Marrero JA.

Liver Transpl. 2007 Nov;13(11):1515-20.

9.

Development of a new head and neck cancer-specific comorbidity index.

Piccirillo JF, Lacy PD, Basu A, Spitznagel EL.

Arch Otolaryngol Head Neck Surg. 2002 Oct;128(10):1172-9.

PMID:
12365889
10.

The impact of comorbidity on outcome in 12 623 Danish head and neck cancer patients: a population based study from the DAHANCA database.

Bøje CR, Dalton SO, Grønborg TK, Primdahl H, Kristensen CA, Andersen E, Johansen J, Andersen LJ, Overgaard J.

Acta Oncol. 2013 Feb;52(2):285-93. doi: 10.3109/0284186X.2012.742964.

PMID:
23320773
11.

A self-report comorbidity questionnaire for haemodialysis patients.

Sridharan S, Berdeprado J, Vilar E, Roberts J, Farrington K.

BMC Nephrol. 2014 Aug 18;15:134. doi: 10.1186/1471-2369-15-134.

12.

Comorbidity measurement in patients with laryngeal squamous cell carcinoma.

Castro MA, Dedivitis RA, Ribeiro KC.

ORL J Otorhinolaryngol Relat Spec. 2007;69(3):146-52. Epub 2007 Jan 30.

PMID:
17264530
13.

Impact of comorbidity on initial treatment and overall survival in elderly head and neck cancer patients.

Chokshi S, Ghobadi A, Athar M, Shah S, Dowell J.

Anticancer Res. 2014 Oct;34(10):5543-6.

PMID:
25275053
14.

The impact of comorbidity and age on survival with laryngeal cancer.

Sabin SL, Rosenfeld RM, Sundaram K, Har-el G, Lucente FE.

Ear Nose Throat J. 1999 Aug;78(8):578, 581-4.

PMID:
10485151
15.

Comorbidity is a prognostic factor in elderly patients with head and neck cancer.

Sanabria A, Carvalho AL, Vartanian JG, Magrin J, Ikeda MK, Kowalski LP.

Ann Surg Oncol. 2007 Apr;14(4):1449-57. Epub 2007 Jan 18.

PMID:
17235712
16.

Validation of the Charlson Comorbidity Index in acutely hospitalized elderly adults: a prospective cohort study.

Frenkel WJ, Jongerius EJ, Mandjes-van Uitert MJ, van Munster BC, de Rooij SE.

J Am Geriatr Soc. 2014 Feb;62(2):342-6. doi: 10.1111/jgs.12635. Epub 2014 Jan 21.

PMID:
24521366
17.

Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study.

Singh B, Bhaya M, Stern J, Roland JT, Zimbler M, Rosenfeld RM, Har-El G, Lucente FE.

Laryngoscope. 1997 Nov;107(11 Pt 1):1469-75.

PMID:
9369392
18.

A comparison of the Charlson comorbidity index derived from medical records and claims data from patients undergoing lung cancer surgery in Korea: a population-based investigation.

Seo HJ, Yoon SJ, Lee SI, Lee KS, Yun YH, Kim EJ, Oh IH.

BMC Health Serv Res. 2010 Aug 13;10:236. doi: 10.1186/1472-6963-10-236.

19.

Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for Lung Cancer.

Singh N, Singh PS, Aggarwal AN, Behera D.

Clin Lung Cancer. 2016 May;17(3):205-213.e1. doi: 10.1016/j.cllc.2015.10.002. Epub 2015 Oct 22.

PMID:
26589440
20.

A matched control study of treatment outcome in young patients with squamous cell carcinoma of the head and neck.

Verschuur HP, Irish JC, O'Sullivan B, Goh C, Gullane PJ, Pintilie M.

Laryngoscope. 1999 Feb;109(2 Pt 1):249-58.

PMID:
10890775

Supplemental Content

Support Center